Alpha lipoic acid attenuates the long-term effects of lead exposure in retinal ischemic injury mouse model.
Alpha lipoic acid
Developmental exposure
Ischemia/reperfusion
Lead toxicity
Retina
Journal
Environmental science and pollution research international
ISSN: 1614-7499
Titre abrégé: Environ Sci Pollut Res Int
Pays: Germany
ID NLM: 9441769
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
07
06
2018
accepted:
25
02
2019
pubmed:
5
4
2019
medline:
3
7
2019
entrez:
5
4
2019
Statut:
ppublish
Résumé
Lead (Pb) exposure is reported to be unsafe for humans. There have been several studies documenting acute and chronic Pb toxicity on the organ systems. New studies suggest that early-life exposure to such environmental toxins may increase the susceptibility to late-onset degenerative disorders. We aimed to examine the long-term effects of early-life postnatal exposure of Pb on retinal degeneration. Pb exposure (200 ppm) was provided either at postnatal day 1 through lactation (early-life exposure) or at 7th week of age (adulthood exposure) directly through drinking water for 20 days. The Pb-treated mice were followed till 20 weeks of age. At 20th week, ischemia/reperfusion (I/R) injury was induced in these mice by pterygopalatine artery ligation. Further, alpha lipoic acid (ALA) was administered to examine its neuroprotective effects against retinal damage. Histological and molecular analysis revealed that Pb-treated mice had greater retinal damage after I/R injury as compared to untreated or ALA treated mice, suggesting that ALA protects the early-life Pb exposure and its consequent impact on later life. The elevated levels of glial derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) and reduced levels of glial fibrillary acidic protein (GFAP) upon ALA pre-treatment suggest that it probably exerts anti-inflammatory effects via upregulation of neurotrophic factors.
Identifiants
pubmed: 30945075
doi: 10.1007/s11356-019-04700-6
pii: 10.1007/s11356-019-04700-6
doi:
Substances chimiques
Ciliary Neurotrophic Factor
0
GDNF protein, human
0
Glial Cell Line-Derived Neurotrophic Factor
0
Glial Fibrillary Acidic Protein
0
Lead
2P299V784P
Thioctic Acid
73Y7P0K73Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15548-15558Subventions
Organisme : Council for Scientific and Industrial Research (CSIR)
ID : 09/135(0666)/2012-EMR-1
Références
Toxicol Lett. 1998 Dec 28;102-103:359-61
pubmed: 10022279
Proc Soc Exp Biol Med. 2000 Mar;223(3):234-40
pubmed: 10719835
J Neurosci. 2000 Aug 1;20(15):5775-81
pubmed: 10908618
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):2036-44
pubmed: 12037016
Brain. 2003 Jan;126(Pt 1):5-19
pubmed: 12477693
Cell Death Differ. 2005 Oct;12(10):1329-43
pubmed: 15905876
Environ Health Perspect. 2005 Jul;113(7):894-9
pubmed: 16002379
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4302-10
pubmed: 16249512
Toxicol Appl Pharmacol. 1991 Jul;109(3):482-93
pubmed: 1649499
Altern Med Rev. 2006 Mar;11(1):2-22
pubmed: 16597190
J Neurosci. 2008 Jan 2;28(1):3-9
pubmed: 18171917
Environ Health Perspect. 2008 May;116(5):618-25
pubmed: 18470321
Neurotoxicology. 2008 Nov;29(6):1069-79
pubmed: 18817812
Neurotherapeutics. 2010 Jan;7(1):51-61
pubmed: 20129497
Biometals. 2010 Oct;23(5):783-92
pubmed: 20354761
PLoS One. 2011 Jan 26;6(1):e16380
pubmed: 21298100
Stem Cells Dev. 2012 Feb 10;21(3):448-54
pubmed: 21561324
Toxicol Appl Pharmacol. 2011 Nov 1;256(3):258-67
pubmed: 21703292
Food Chem Toxicol. 2011 Nov;49(11):2750-7
pubmed: 21843584
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18430-5
pubmed: 22025720
Invest Ophthalmol Vis Sci. 2011 Dec 28;52(13):9710-20
pubmed: 22110078
Front Pharmacol. 2011 Nov 17;2:69
pubmed: 22125537
J Toxicol. 2012;2012:132671
pubmed: 22287959
Invest Ophthalmol Vis Sci. 2012 Sep 06;53(10):5976-84
pubmed: 22871829
N Engl J Med. 1990 Jan 11;322(2):83-8
pubmed: 2294437
Interdiscip Toxicol. 2012 Jun;5(2):47-58
pubmed: 23118587
Exp Neurol. 2013 Feb;240:75-87
pubmed: 23123407
Nat Rev Neurol. 2013 Jan;9(1):44-53
pubmed: 23165340
Eur J Pharmacol. 2013 Mar 5;703(1-3):1-10
pubmed: 23428630
Exp Eye Res. 2013 Aug;113:49-59
pubmed: 23726881
J Neuroinflammation. 2013 Dec 10;10:149
pubmed: 24325836
Lancet Neurol. 2014 Mar;13(3):330-8
pubmed: 24556010
Exp Eye Res. 2014 Aug;125:156-63
pubmed: 24954538
Mol Med Rep. 2015 May;11(5):3659-65
pubmed: 25572614
Mol Brain. 2015 Feb 11;8:9
pubmed: 25761600
Mol Neurobiol. 2016 Sep;53(7):4961-71
pubmed: 26374550
Ann Neurosci. 2015 Oct;22(4):222-5
pubmed: 26526209
Int J Environ Res Public Health. 2016 Mar 25;13(4):358
pubmed: 27023578
Curr Eye Res. 2016 Nov;41(11):1465-1472
pubmed: 27158842
J Vis Exp. 2016 Jul 14;(113):
pubmed: 27501124
Neurotoxicology. 2016 Dec;57:145-152
pubmed: 27663850
J Cell Biochem. 2017 Jul;118(7):1699-1711
pubmed: 27935095
Mol Vis. 2016 Dec 24;22:1468-1489
pubmed: 28050121
J Cell Biochem. 2017 Oct;118(10):3213-3224
pubmed: 28262968
J Neuropathol Exp Neurol. 1984 Mar;43(2):175-87
pubmed: 6608578